Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Pulmonary Disease, Chronic Obstructive 1Pneumonia 1Colonic Neoplasms 1

Interventions

Cisplatin 274pembrolizumab 229Radiotherapy 166Cetuximab 163Carboplatin 122Docetaxel 109Paclitaxel 94Fluorouracil 94Nivolumab 84Radiotherapy, Intensity-Modulated 78Magnetic Resonance Spectroscopy 39durvalumab 35Radiation 32Surgical Procedures, Operative 31Drug Therapy 30Radiosurgery 25Erlotinib Hydrochloride 25Biopsy 25Albumin-Bound Paclitaxel 24130-nm albumin-bound paclitaxel 24Taxes 23Platinum 22Specimen Handling 21tislelizumab 201,2-diaminocyclohexaneplatinum II citrate 20Cyclophosphamide 19Capecitabine 19tremelimumab 18Ipilimumab 18Gemcitabine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Squamous Cell Carcinoma of Head and Neck × CIMAvax EGF × Clear all
NCT02955290 2025-11-10

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
51 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡